BioLineRx (BLRX) Reports In-Line Q1 EPS

BioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $0 versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
• Cracker Barrel (CBRL) Tops Q3 EPS by 71c